Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
UBS
Cipla
Argus Health
Johnson and Johnson
Healthtrust
Fuji
Cantor Fitzgerald
Mallinckrodt

Generated: July 15, 2018

DrugPatentWatch Database Preview

VIZAMYL Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Vizamyl patents expire, and what generic alternatives are available?

Vizamyl is a drug marketed by Ge Healthcare and is included in one NDA. There are five patents protecting this drug.

This drug has seventy-six patent family members in twenty-three countries.

The generic ingredient in VIZAMYL is flutemetamol f-18. One supplier is listed for this compound. Additional details are available on the flutemetamol f-18 profile page.
Summary for VIZAMYL
International Patents:76
US Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 1
Clinical Trials: 3
Patent Applications: 14
DailyMed Link:VIZAMYL at DailyMed
Drug patent expirations by year for VIZAMYL
Generic Entry Opportunity Date for VIZAMYL
Generic Entry Date for VIZAMYL*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage::
INJECTABLE;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for VIZAMYL
Synonyms for VIZAMYL
((18 sup)F)AH110690
[18F]-Flutemetamol
[18F]-Flutemetamol F18
[18F]AH110690
[18F]flutemetamol
18F-Flutemetamol
2-(3-((18 sup)F)Fluoro-4-(methylamino)phenyl)-1,3-benzothiazol-6-ol
2-(3-(sup 18)f)Fluoro-4-(methylamino)phenyl)-1,3-benzothiazol-6-ol
2-[3-((18)F)fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol
2-[3-(18F)fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol
6-Benzothiazolol, 2-(3-(fluoro-(sup 18)F)-4-(methylamino)phenyl)-
765922-62-1
CHEBI:76611
CHEMBL2042122
D10231
DB09151
DTXSID80227394
Flutemetamol
flutemetamol ((18)F)
Flutemetamol ((sup 18)F)
Flutemetamol ((sup18)F)
flutemetamol (18F)
Flutemetamol (18F) [INN]
Flutemetamol F 18
Flutemetamol F 18 (USAN)
Flutemetamol F 18 [USAN]
flutemetamol F 18 injection
Flutemetamol F-18
Flutemetamol F18
GTPL7342
L49M066S0O
SCHEMBL10032147
UNII-L49M066S0O
Vizamyl (TN)

US Patents and Regulatory Information for VIZAMYL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for VIZAMYL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,833,458 Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition ➤ Sign Up
7,854,920 Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition ➤ Sign Up
9,134,328 Methods of using benzothiazole derivative compounds and compositions ➤ Sign Up
8,911,707 Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for VIZAMYL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 Austria ➤ Sign Up PRODUCT NAME: (18F) - FLUTEMETAMOL; REGISTRATION NO/DATE: EU/1/14/941 (MITTEILUNG) 20140826
90009-5 Sweden ➤ Sign Up PRODUCT NAME: FLUTEMETAMOL (18F); REG. NO/DATE: EU/1/14/941 20140826
0150004 00139 Estonia ➤ Sign Up PRODUCT NAME: FLUTEMETAMOOL (18F);REG NO/DATE: EU/1/14/941 26.08.2014
2015001 Lithuania ➤ Sign Up PRODUCT NAME: FLUTEMETAMOLUM (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Johnson and Johnson
Farmers Insurance
Moodys
Cantor Fitzgerald
Medtronic
Express Scripts
Covington
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.